PROM1, prominin 1, 8842

N. diseases: 477; N. variants: 33
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE CD133 is an investigated surface marker for cancer stem-like cells (CSCs) that may be involved in tumor initiation in head and neck carcinomas. 29909565 2019
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 AlteredExpression phenotype BEFREE The ZnAs@SiO<sub>2</sub> NPs also inhibited tumor spheroid formation <i>in vitro</i> and tumor initiation <i>in vivo</i> and induced significant changes in the expression of stemness markers (CD133, Sox-2, and Oct-4) and EMT markers (E-cadherin, Vimentin, and Slug) both <i>in vitro</i> and <i>in vivo.</i> These effects of ZnAs@SiO<sub>2</sub> that correlated with prognosis of HCC were mediated by the SHP-1/JAK2/STAT3 signaling. 31285768 2019
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE CD133 is a widely used cell surface marker of cancer stem cells that plays an important role in tumor initiation and metastasis. 30873590 2019
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE Their characteristics were investigated through colony formation, spheres formation, chemoresistance, flow cytometry for putative stem cell markers, such as CD133, CD34 and CD45, immunofluorescence staining and tumor initiation capacity <i>in vivo</i>. 29887968 2018
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 AlteredExpression phenotype BEFREE Knocking down OPN significantly inhibited the sphere formation and stemness-related genes expression, and delayed tumor initiation of CD133+/CD44+ subgroup of HCC cells. 30064482 2018
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE CD133 (Prominin-1), a stem cell marker implicated in tumor initiation, differentiation and resistance to anti-cancer therapy, is reportedly associated with EVs in various types of cancer. 28452069 2017
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE In tumorigenesis, NCAM1(+)CD133(-) marks SIX2(+) blastema that includes the ALDH1(+) WT cancer stem/initiating cells, while NCAM1(+)CD133(+) and NCAM1(-)CD133(+) specifying early and late epithelial differentiation, are severely restricted in tumor initiation capacity and tumor self-renewal. 27020553 2016
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE Among the biomarkers of CSCs, CD-133 (prominin-1) has been known to effectively isolate CSCs from cancer population, including GBM; however, the underlying mechanism of how stemness genes manipulate CSC-associated phenotypes, such as tumor initiation and relapse, is still unclear. 27530866 2016
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE CD133(+) cells demonstrated a trend for increased tumor initiation while CD24(+) cells versus CD24(-) cells had significantly greater tumor initiation and tumor growth capacity. 25969154 2015
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE CD133(+) cells possess strong tumorigenicity, responsible for tumor initiation and maintenance. 24271022 2013
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE CD133 is a marker that identifies/enriches cancer stem cell implicated in tumor initiation. 23408993 2013
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE Tumor cell subpopulations that express cancer stem cell markers such as CD133 (prominin1) or ABCB5 are thought to be crucial for tumor initiation and heterogeneity, but their biological significance in melanoma has been controversial. 22865455 2012
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE These findings either imply that (i) AC133-positive and AC133-negative glioma cells comprise different, independent CSC populations, (ii) AC133-positive glioma cells are derived from primordial AC133-negative CSCs or (iii) AC133-negative CSCs have lost AC133 expression, while retaining their stem-like features and tumor initiation capacity, and can reacquire AC133 expression in vivo. 20853315 2011
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE In addition to in vitro studies, in vivo tumor initiation experiments confirmed that CD133-sorted cells implanted into the flanks of nude mice grew faster and larger than unsorted cells. 21862685 2011
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation
0.100 Biomarker phenotype BEFREE Most important, TGFbeta1-induced CD133+ Huh7 cells demonstrate increased tumor initiation in vivo. 20196115 2010